Active, not recruitingPhase 2NCT02682511

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cumberland Pharmaceuticals
Principal Investigator
Evan Brittain, MD
Vanderbilt University Medical Center
Intervention
Oral Ifetroban(drug)
Enrollment
34 enrolled
Eligibility
18-80 years · All sexes
Timeline
20172026

Study locations (13)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02682511 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials